Crescita Reports Q4 and Fiscal 2019 Results
Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M LAVAL, QC , March 18, 2020 |CNW| - Crescita Therapeutics Inc. (TSX: CTX ) (GREY: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research development ("RD") and manufacturing capabilities, today reported its financial results for the fourth quarter ("Q4-F2019") and fiscal year ended December 31, 2019 ("F2019"). All amounts are in thousands of Canadian dollars except for share and per share amounts, unless otherwise noted. Year-over-year Financial Highlights F2019 vs. F2018 Record revenue of $22,337 , an increase of $5,709 or 34.3%
Crescita Reports Q4 and Fiscal 2019 Results
Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M LAVAL, QC , March 18, 2020 |CNW| - Crescita Therapeutics Inc. (TSX: CTX ) (GREY: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research development ("RD") and manufacturing capabilities, today reported its financial results for the fourth quarter ("Q4-F2019") and fiscal year ended December 31, 2019 ("F2019"). All amounts are in thousands of Canadian dollars except for share and per share amounts, unless otherwise noted. Year-over-year Financial Highlights F2019 vs. F2018 Record revenue of $22,337 , an increase of $5,709 or 34.3%